[ JUDGEMENT, NOT GENERATION ]
Less information.
Better thinking.
Every other AI generates more to read. Marshy reads your team's reasoning back and shows where it breaks, before the decision ships.
- Never trains on your data
- GDPR compliant
- Judgement stays with you
We're doing IP diligence on a biologic in-licensing deal. The target's patent estate is the main attraction, broad claims lock up the whole class, nobody else gets in. Deal's priced off that exclusivity to the mid-2030s.
- HIGH
You've adopted the seller's framing: Under Amgen, breadth is not strength, it's exposure, because the broader the functional genus the harder the enablement burden.
- WATCH
Issued-and-tested is not issued-and-untested: A genus claim that has survived a PTAB challenge is worth paying for; one that hasn't is a lottery ticket priced as a bond.
- HIGH
The durable asset is the afterthought: The composition-of-matter claim is the value floor and the genus claim is the option premium, and they're priced backwards.
- 11-section report
- EMA · FDA · HTA mapped
- 90-second run
- Report you can hand to a client
How it works
Bring a decision
One live call, memo, or deck summary.
Marshy pre-runs it
Eleven sections, severity tags, blind spots.
We work it through
A session on what it caught.
A typical session
- You bring one live decision or memo
- Marshy pre-runs it across eleven sections
- Risks surface with severity tags
- Senior questions you will face in the room
What you leave with
- A scored Marshy Rating on your thinking
- Named gaps before they become expensive
- A reference pack you can share internally
- Clear next steps, not more slides
It doesn't do the work.
It makes sure the work is right.
Plan the targets
Direct the diligence
Keep the team on the ball
Sanitised example · M&A / financial strategy
Acquiring a $40bn generics business to diversify off a patent cliff
A branded pharma weighing a mostly-cash, bridge-funded acquisition to become the biggest generics player globally, with the board already supportive. Marshy took the financial case as stated and stress-tested it the way the board's own advisors would.
$1.4bn
Synergy claim
Flagged as run-rate, not a delivery curve, and untested against cost-to-achieve
3+ yrs
Timing mismatch
Synergy capture lands years after the cliff hits branded cash flow
5 questions
The board will ask
Gross-vs-net synergy, a Teva-2017 downside scenario, post-close credit rating, and more
Your decisions stay yours. Nothing you run is trained on or shared.
See it live
Bring one live decision. See what it catches.
A working session on a real call you're weighing. No commitment.
MarshyOS is operated by MarshyOS Ltd, a UK-incorporated company. Your decisions and data remain confidential by default and are never used to train the model. First session is on us; pricing is set with you once you've seen what it catches.